NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has raised $1.1 million toward a targeted $2.5 million financing round.

The company disclosed the raise in a document filed with the US Securities and Exchange Commission this week. A spokesman told GenomeWeb Daily News that the Pittsfield, Mass.-based firm plans to close the $2.5 million round at the end of next month. He said that Nuclea would not be disclosing who the investors are or how the funds from the financing would be used until then.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.